Juvenile parkinsonism

Seminars in Pediatric Neurology

Volumn 10, Issue 1, 2003, Pages 62-67

  Uc, Ergun Y ^a   Rodnitzky, Robert L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BENSERAZIDE; BENZATROPINE; BROMOCRIPTINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DOMPERIDONE; ENTACAPONE; FLUDROCORTISONE; LEVODOPA; MIDODRINE; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; ROPINIROLE; SELEGILINE; SODIUM CHLORIDE; TOLCAPONE; TRIHEXYPHENIDYL;

ATAXIA; CHILD; CLINICAL FEATURE; COGNITIVE DEFECT; DISEASE CLASSIFICATION; DRUG MECHANISM; DYSTONIA; EYE MOVEMENT DISORDER; HALLUCINATION; HEPATOSPLENOMEGALY; HEREDITY; HUMAN; LIVER DYSFUNCTION; LIVER FAILURE; METABOLIC DISORDER; NAUSEA; NEUROPATHOLOGY; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PSYCHOSIS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; VERTIGO; VISUAL DISORDER; VOMITING;

EID: 0038824082     PISSN: 10719091     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9091(02)00011-6     Document Type: Review

References (56)

1. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol 56:33-39, 1999
2. Rodnitzky RL, Uc EY: Approach to the hypokinetic patient, in Biller J (ed): Practical Neurology. Philadelphia, Lippincott Williams & Wilkins, 2002, pp 343-357
3. Lang AE, Lozano AM: Parkinson's disease (part 1). N Engl J Med 339:1044-1053, 1998
4. Tanner CM, Goldman SM: Epidemiology of Parkinson's disease. Neurol Clin 14:317-335, 1996
5. Zhang ZX, Roman GC: Worldwide occurrence of Parkinson's disease: An updated review. Neuroepidemiology 12:195-208, 1993
6. Golbe LI: Young-onset Parkinson's disease: A clinical review. Neurology 41(pt 1):168-173, 1991
7. Muthane UB, Swamy HS, Satishchandra P, et al: Early-onset Parkinson's disease: Are juvenile and young-onset different? Mov Disord 9:539-544, 1994
8. Schrag A, Ben Shlomo Y, Brown R, et al: Young-onset Parkinson's disease revisited: Clinical features, natural history, and mortality. Mov Disord 13:885-894, 1998
9. Quinn N, Critchley P, Marsden CD: Young-onset Parkinson's disease. Mov Disord 2:73-91, 1987
10. Lima B, Neves G, Nora M: Juvenile parkinsonism: Clinical and metabolic characteristics. J Neurol Neurosurg Psychiatry 50:345-348, 1987
11. Willage R: Uber paralysis agitans in jugendlichem. Neurol Psychiatric 4:520-587, 1911 (in German)
12. Cardoso F, Camargos S: Juvenile parkinsonism: A heterogeneous entity. Eur J Neurol 7:467-471, 2000
13. Langston JW, Tan LC: Juvenile parkinsonism: A term in search of an identity. Eur J Neurol 7:465-466, 2000
14. Pranzatelli MR, Mott SH, Pavlakis SG, et al: Clinical spectrum of secondary parkinsonism in childhood: A reversible disorder. Pediatr Neurol 10:131-140, 1994
15. Yokochi M, Narabayashi H, Iizuka R, et al: Juvenile parkinsonism: Some clinical, pharmacological, and neuropathological aspects. Adv Neurol 40:407-413, 1984
16. Bernheimer H, Birkmayer W, Hornykiewicz O, et al: Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455, 1973
17. Carlier G, Dubru JM: Familial juvenile Parkinsonism. Acta Paediatr Belgica 32:123-127, 1979
18. Sachdev KK, Singh N, Krishnamoorthy MS: Juvenile parkinsonism treated with levodopa. Arch Neurol 34:244-245, 1977
19. Martin WE, Resch JA, Baker AB: Juvenile parkinsonism. Arch Neurol 25:494-500, 1971
20. Ishikawa A, Miyatake T: A family with hereditary juvenile dystonia-parkinsonism. Mov Disord 10:482-488, 1995
21. Naidu S, Wolfson LI, Sharpless NS: Juvenile parkinsonism: A patient with possible primary striatal dysfunction. Ann Neurol 3:453-455, 1978
22. Clough CG, Mendoza M, Yahr MD: A case of sporadic juvenile Parkinson's disease. Arch Neurol 38:730-731, 1981
23. Gershanik OS, Leist A: Juvenile-onset Parkinson's disease. Adv Neurol 45:213-216, 1987
24. Yamamura Y, Sobue I, Ando K, et al: Paralysis agitans of early onset with marked diurnal fluctuation of symptoms. Neurology 23:239-244, 1973
25. Hattori N, Matsumine H, Asakawa S, et al: Point mutations (Thr240Arg and Gln311Stop) in the parkin gene. Biochem Biophys Res Commun 249:754-758, 1998
26. Lucking CB, Abbas N, Durr A, et al: Homozygous deletions in the parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. Lancet 352:1355-1356, 1998
27. Lucking CB, Durr A, Bonifati V, et al: Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med 342:1560-1567, 2000
28. Kitada T, Asakawa S, Hattori N, et al: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608, 1998
29. Imai Y, Soda M, Takahashi R: Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275:35661-35664, 2000
30. Shimura H, Hattori N, Kubo S, et al: Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25:302-305, 2000
31. Zhang Y, Gao J, Chung KK, et al: Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCre1-1. Proc Nat Acad Sci U S A 97:13354-13359, 2000
32. Choi P, Golts N, Snyder H, et al: Co-association of parkin and alpha-synuclein. Neuroreport 12:2839-2843, 2001
33. Shimura H, Schlossmacher MG, Hattori N, et al: Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease. Science 293:263-269, 2001
34. Chung KK, Zhang Y, Lim KL, et al: Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson disease. Nat Med 7:1144-1150, 2001
35. Farrer M, Chan P, Chen R, et al: Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 50:293-300, 2001
36. Hattori N, Kitada T, Matsumine H, et al: Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the parkin gene in affected individuals. Ann Neurol 44:935-941, 1998
37. Hardie RJ, Lees AJ: Neuroleptic-induced Parkinson's syndrome: Clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51:850-854, 1998
38. Luque FA, Selhorst JB, Petruska P: Parkinsonism induced by high-dose cytosine arabinoside. Mov Disord 2:219-222, 1987
39. Devinsky O, Lemann W, Evans AC, et al: Akinetic mutism in a bone marrow transplant recipient following total-body irradiation and amphotericin B chemoprophylaxis: A positron emission tomographic and neuropathologic study. Arch Neurol 44:414-417, 1987
40. Boranic M, Raci F: A Parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukaemia. Biomedicine 31:124-125, 1979
41. Wasserstein PH, Honig LS: Parkinsonism during cyclosporine treatment. Bone Marrow Transplant 18:649-650, 1996
42. Rodnitzky RL: Drug-induced movement disorders. Clin Neuropharmacol 25:142-152, 2002
43. Scott M: Parkinsonian-like and cogwheel rigidity in a child secondary to massive ependymoma of the frontal lobe and the caudate nucleus: Prefrontal lobectomy, with cessation of tremor and rigidity. Arch Neurol Psychiatry 57:649-651, 1947
44. Shahar E, Lambert R, Hwang PA, et al: Obstructive hydrocephalus-induced parkinsonism. I: Decreased basal ganglia regional blood flow. Pediatr Neurol 4:117-119, 1988
45. Brazin ME, Epstein LG: Reversible parkinsonism from shunt failure. Pediatr Neurol 1:306-307, 1985
46. Lang AE, Meadows JC, Parkes JD, et al: Early onset of the "on-off" phenomenon in children with symptomatic parkinsonism. J Neurol Neurosurg Psychiatry 45:823-825, 1982
47. Dickman MS: von Economo encephalitis. Arch Neurol 58:1696-1698, 2001
48. McCall S, Henry JM, Reid AH, et al: Influenza RNA not detected in archival brain tissues from acute encephalitis lethargica cases or in postencephalitic Parkinson cases. J Neuropathol Exp Neurol 60:696-704, 2001
49. Misra UK, Kalita J: Prognosis of Japanese encephalitis patients with dystonia compared to those with parkinsonian features only. Postgrad Med J 78:238-241, 2002
50. Sawaishi Y, Yano T, Watanabe Y, et al: Migratory basal ganglia lesions in subacute sclerosing panencephalitis (SSPE): Clinical implications of axonal spread. J Neurol Sci 168:137-140, 1999
51. Kim JS, Choi IS, Lee MC: Reversible parkinsonism and dystonia following probable mycoplasma pneumoniae infection. Mov Disord 10:510-512, 1995
52. Rasmussen A, Macias R, Yescas P, et al: Huntington disease in children: Genotype-phenotype correlation. Neuropediatrics 31:190-194, 2000
53. Siesling S, Vegter-van der Vlis M, Roos RA: Juvenile Huntington disease in the Netherlands. Pediatr Neurol 17:37-43, 1997
54. Lang AE, Lozano AM: Parkinson's disease (part 2). N Engl J Med 339:1130-1143, 1998
55. Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 284:1931-1938, 2000
56. Rascol O, Brooks DJ, Korczyn AD, et al: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa: 056 study group. N Engl J Med 342:1484-1491, 2000